Background {#Sec1}
==========

Hepatitis B virus (HBV) and HCV infection are major causes of chronic liver disease globally and together account for about for about 1.34 million deaths per year, mainly from cirrhosis or hepatocellular carcinoma \[[@CR1], [@CR2]\]. The recent development of highly effective, well-tolerated oral treatment regimens with high rates of cure after 12 weeks of treatment has revolutionized the treatment of chronic HCV infection \[[@CR3]\]. Effective long-term antiviral treatment with tenofovir or entecavir is also available for people with chronic HBV infection \[[@CR4], [@CR5]\]. Despite the high burden of disease and treatment advances, the majority of people infected with HBV \[[@CR6], [@CR7]\] and HCV \[[@CR8]--[@CR10]\] remain unaware of their infection. Estimates from the 2017 Global Hepatitis Report indicated that only 9% of persons living with HBV (22 million) and 20% of persons living with HCV (14 million) had been tested and were aware of their diagnosis \[[@CR2]\]. There are several potential reasons for insufficient hepatitis testing, including limited facilities for hepatitis testing, lack of national testing policies, costly diagnostic assays, complicated diagnostic algorithms, and inadequate quality assurance systems. A further barrier has been the lack of service delivery models for hepatitis testing in different settings and populations.

There are many potential facility or community based approaches to delivery hepatitis testing \[[@CR11]\]. Facility-based opportunities include primary care and outpatient clinics such as specialist clinics (e.g., HIV, TB and STI clinics), inpatient services, and private services. Community based testing can be offered through outreach and mobile programmes in schools and workplaces. Although many of these approaches were developed to expand HIV testing \[[@CR12]\], some of these may also be relevant to expand viral hepatitis testing. WHO has recently developed evidence-based testing guidelines for hepatitis B and C virus infection \[[@CR13]\]. The evidence-base included several systematic reviews but recommendations were also based on consideration of overall benefits and harms, cost-effectiveness, resource use, acceptability, and programmatic feasibility using the GRADE criteria \[[@CR14]\]. However, in contrast to HIV care for which there is an extensive literature on different options for HIV testing through health facilities and in different populations, there is limited published literature on programmatic experience of hepatitis testing \[[@CR11], [@CR13]\]. To address the limited published literature and evidence-base to support different service delivery approaches to hepatitis testing in the World Health Organization Hepatitis Testing Guidelines, we used an innovation contest to solicit a range of approaches to hepatitis B and C testing. Innovation contests allow communities to identify novel approaches to implementing public health interventions, often with the help of the internet and multisectoral partnerships \[[@CR15]\]. The goal of the contest was to enrich the guidelines with real-world practices in different settings and populations. Previous health-focused innovation contests solicited public health concepts, images \[[@CR16], [@CR17]\], and videos \[[@CR18], [@CR19]\] to promote public health campaigns in support of HIV testing \[[@CR16], [@CR19]\], healthy sexual behavior \[[@CR16], [@CR20], [@CR21]\], healthy eating habits \[[@CR22]--[@CR24]\], regular sunscreen use \[[@CR25], [@CR26]\] and smoking cessation \[[@CR27]--[@CR29]\].

Common themes of these contests are the issuing of an open call for entries, engaging a range of individuals and groups, evaluation of entries, and recognition of finalists \[[@CR16], [@CR30]\]. The purpose of this paper is to describe the methodology of an innovation contest and key findings from the range of submissions.

Methods {#Sec2}
=======

Innovation contests {#Sec3}
-------------------

The innovation contest was organized through a collaboration between SESH (Social Entrepreneurship for Sexual Health) and the World Health Organization Global Hepatitis Programme. SESH has organized a total of 16 innovation contests \[[@CR16], [@CR18], [@CR30]\]. The contest was initiated on December 15th 2015 with the formation of a steering committee and was completed on April 17th 2016 with the announcement of finalists and issuing of commendation certificates at the 2016 European Association for the Study of the Liver (EASL) conference. The contest had several discrete steps: 1) establishment of a multisectoral steering committee to plan the contest; 2) dissemination of the call for entries through diverse media; 3) independent evaluation and ranking of entries by a panel of judges according to pre-specified criteria; 4) recognition of contestants through commendation and case studies in the WHO testing guidelines.

Establishment of a multisectoral steering committee to plan the contest {#Sec4}
-----------------------------------------------------------------------

A multisectoral steering committee was established with representation from key stakeholders and geographic regions. These included WHO (HQ Global Hepatitis Programme and regional office focal points in hepatitis), public health experts, implementing partners, social media and communications experts, and advocacy organisations. The steering committee guided the overall development, evaluation, and promotion of the contest coordinated through a series of teleconferences. An open call was made January 15th 2016 that explained the purpose of the contest and solicited short descriptions of programmes to promote hepatitis B and C testing. Entries were to include a description of the testing model; a description of how it is novel with regard to promoting uptake of testing in either setting, population or education; data to support evidence of effectiveness and impact of programme, including linkage to care; and next steps for continuing the work and ensuring sustainability (Additional file [1](#MOESM1){ref-type="media"}). Eligible entries were those that described existing ongoing programmes. The announcement was translated into the six UN languages (French, Chinese, Arabic, Russian, Spanish, English) and included a link to a one-minute video explaining the contest, its purpose, and how people could contribute (Additional file [1](#MOESM1){ref-type="media"}). The hashtag "HepTestContest" identified the campaign on social media platforms. All contestants were also asked to complete a brief online survey that asked when their testing programme started, what proportion of the organization's work was focused on hepatitis, the availability of direct acting antivirals in their country, whether or not they also provided HIV testing, and perceived barriers to testing.

Dissemination of the call for entries through diverse media {#Sec5}
-----------------------------------------------------------

In order to disseminate the call for entries widely, we used several social media platforms (Twitter, Facebook, and YouTube), as well as the email listservs and networks of collaborating organisations represented by the steering committee. The call for entries was also included in two academic journals, *Journal of Virus Eradication* and *Hepatitis, Policy, and Medicine*. The hashtag "HepTestContest" was used to identify the campaign on social media platforms. We used real-time social media analytics from a video hosting site, innovation contest webpage, Twitter hashtag activity, and submissions to assess both total and regional engagement during the 6 weeks of soliciting entries.

Independent evaluation of entries by a panel of judges according to pre-specified criteria {#Sec6}
------------------------------------------------------------------------------------------

In addition to the Steering committee members, additional persons were invited to participate in rating the entries to increase representation from under-represented regions and community-based organizations (CBOs). A total of sixteen judges participated. Each judge independently rated each of the four parts of the abstract submission on a 1-10 scale: description of testing model, innovation, effectiveness, and next steps for sustainability, with 10 indicating a high and 1 a low score. In addition, each judge gave an overall score of 1-10. Judges who had a conflict of interest with a programme recused themselves from reviewing that entry. The three non-English entries were evaluated by judges proficient in the language of the entry. Conflicts were defined as collaborating, co-authoring, helping, receiving or providing monetary or other support, or anything that could be perceived as a conflict of interest. Judges entered their scores into an online scorecard developed in SurveyGizmo (Boulder, USA), a software programme for creating online surveys. The software facilitated data analysis and provided a common platform to securely enter scores. An overall mean score that averaged the means for each of the four subcomponents (testing model, innovation, effectiveness, next steps) was calculated.

Recognition of a subset of contestants through commendation and inclusion in the WHO testing guidelines {#Sec7}
-------------------------------------------------------------------------------------------------------

Entries that received an overall mean score of greater than 6.0 (a threshold determined by the Steering Committee, representing 15% of all submissions) on the 1-10 scale received a commendation of excellence from EASL, on behalf of the Innovation Contest Steering Committee, SESH and WHO. In addition, five of the finalists were invited to present their testing innovations at the 2016 International Liver Congress (ILC)/EASL in Barcelona, Spain. One finalist also presented at the International AIDS Society conference (21 July 2016) in Durban, South Arica and at the World Hepatitis Day (28 July 2016) in Mumbai, India. In addition, selected submissions were included as case studies in the chapter on service delivery within the WHO hepatitis testing guidelines.

Results {#Sec8}
=======

Key characteristics of contest entries {#Sec9}
--------------------------------------

We received 64 entries from 27 countries in all WHO regions (Fig. [1](#Fig1){ref-type="fig"}). Among the 31 commended entries, these included two from Africa (one from Egypt, one from Nigeria), nine from Asia (three from India, two from Australia, one from Malaysia, one from Indonesia, one from Mongolia, one from China), six from Europe (three from the UK, one from Georgia, one from the Netherlands), and 14 from North America (all 14 from the US). Among commended entries, 12/31 (39%) were from non-government organizations, 10/31 (33%) were from hospitals, 6/31 (19%) were from research organizations, and 4/31 (13%) were from governmental organizations. Nearly all (61/64) entries were in English and we received one entry in Portuguese, one in Russian, and one in Chinese. Of the 64 entries, 21 (33%) tested for hepatitis B and C, 25 (39%) for hepatitis C only, and 10 (16%) for hepatitis B only. A total of 10/64 (16%) only tested for hepatitis B, 25/64 (39%) only tested for hepatitis C, and 21/64 (33%) tested for both. The median number of persons tested through each entry was 1367 (range 90 -- 240,188) among the 39 entries that reported testing numbers. A majority (42/64, 66%) of entries were from testing programmes initiated in the past 3 years and most (45/64, 71%) programmes also provided HIV testing.Fig. 1Map of countries with contributions to the hepatitis testing innovation contest

The 64 entries demonstrated a broad range of testing locations, populations, and service models (Table [1](#Tab1){ref-type="table"}). In terms of testing locations, 18 programmes were based at clinical facilities; 11 were at non-clinical sites; two tested at courthouses or prisons; and one in the workplace. Populations tested in different programmes included six testing people who inject drugs (PWID); four in pregnant women; three among the general population; three in high-risk groups; two among relatives of people living with hepatitis B and C; two among migrants; two in incarcerated individuals. Eight used electronic medical records in primary care to flag higher-risk populations for testing. Five used social media to promote uptake of testing. In terms of service models, several programmes employed well--established health system programming practices to support testing scale-up, including delivery of integrated testing (12 HIV-hepatitis, and 9 with harm reduction or addiction services); task sharing (*n* = 8) and decentralisation (*n* = 8); and use of task shifting of testing activities to other cadres of health workers (*n* = 8).Table 1Commended entries from the global hepatitis testing innovation contest, 2016, organized by region (*n* = 31)ContinentCountryOrganization (Organization Type)HBV/HCVPopulation TestedSettingKey feature of service deliveryHealth system programme practicesAfricaEgyptAssociation of Liver Patients Care (NGO) and the Egyptian Liver Hospital (Hospital)HBV/HCVGeneral populationCommunity (non-clinical)SMS promotion\
Community empowermentSocial marketing, decentralizationAfricaNigeriaFederal Ministry of Health (Government)HBV/HCVGeneral populationCommunity (non-clinical)Social mediaSMS promotion, public-private partnership, task shiftingAsiaIndiaCommunity Network for Empowerment (NGO)HCVPWID, PLHIV, outpatientsCommunity (clinical and non-clinical)Community empowermentDecentralization, task shifting, public-private partnershipAsiaMongoliaFlagstaff International Relief Effort (NGO)HBV/HCVHealth care workers, social workers, and family history of liver cancerPrimary care clinicsIntegration with primary careDecentralization, integration with HBV immunizationAsiaIndiaInstitute of Liver and Biliary Sciences (Research)HBV/HCVFirst degree relatives of HBV+ patients; PWIDHealth facility clinicsFamily-focused test promotionIntegration with HBV immunization, task shiftingAsiaIndiaMedecins Sans Frontieres (NGO)HCVPLHIVHealth facility clinicsHIV-hepatitis integrationTask shiftingAsiaIndonesiaPersaudaraan Korban Napza Indonesia (NGO)HCVPWIDUrban sitesPeer-basedHIV-hepatitis integration, addiction service integrationAsiaAustraliaSt Vincent's Hospital Melbourne and Justice Department, Victorian State Government (Hospital)HCVPrisoners on entry or transferPrisonPrison-based telemedicineIntegration with primary care and addiction servicesAsiaAustraliaThe Kirby Institute, UNSW Australia (Research)HCVPWIDCommunity (clinic and non-clinical)Social mediaSocial marketing, addiction service integrationAsiaMalaysiaUniversity of Malaya-Center of Excellence for Research in AIDS (Research)HCVPWIDMethadone clinicMethadone clinic-based servicesHarm reduction/addiction service integration, peer-basedAsiaChinaYunnan AIDS Initiative (NGO)HBVPregnant women and partnersMaternal and child health clinicsPrenatal service integrationHIV-hepatitis integrationEuropeUKBarts Health NHS Trust (Hospital)HBV/HCVEmergency department patientsEmergency departmentSocial mediaHIV-hepatitis integration, public-private partnershipEuropeUKChelsea and Westminster Hospital (Hospital)HBV/HCVEmergency department patients (HIV-negative)Emergency departmentEMR, simplified pathway for emergency department testingHIV-hepatitis integration,EuropePortugalIN-Mouraria (NGO)HBV/HCVPWIDSubstance abuse programsComprehensive harm reduction services for PWIDHIV-hepatitis integration, addiction service integration, peer-based, task shiftingEuropeUKJames Cook University Hospital (Hospital)HBV/HCVGeneral populationHealth facility clinicsEMRHIV-hepatitis integrationEuropeGeorgiaGeorgian Harm Reduction Network (NGO)HCVPWIDOutreach mobile sitesMethadone-based service delivery for PWIDDecentralization, public-private partnership, task shiftingEuropeNetherlandsPublic Health Service of Amsterdam (Government)HCV"At Risk" based on questionnaireHealth facility clinicsWeb-based risk stratification and referralUse of social media to promote accessNorth AmericaUSEmory University/Grady Health System: Grady Liver Clinic (Research/Hospital)HCVBirth year (1945-1965)Primary care clinicsEMRDecentralizationNorth AmericaUSHep Free Hawaii (NGO)HBV/HCVGeneral populationPharmaciesEMRUse of social media to promote access, decentralizationNorth AmericaUSHorizon Health Center (Hospital)HCVNew hospital and clinic patients/and untested for HIV in previous 12 monthsHealth facility clinicsEMRHIV-hepatitis integrationNorth AmericaUSImagine Hope (NGO)HCVPWIDMethadone clinics and substance abuse programmesAddiction service integrationHIV-hepatitis integration, public-private partnershipNorth AmericaUSKaiser Permanente Mid-Atlantic States (Hospital)HCVGeneral population & birth yearPrimary care clinicsEMRHIV-hepatitis integrationNorth AmericaUSMemorial Hermann Healthcare System (Hospital)HCVBirth cohort (1945-1965)Emergency departmentEMRHIV-hepatitis integration, public-private partnershipNorth AmericaUSNational Nursing Centers Consortium (NGO)HCVOutpatientsPrimary care clinicsEMRHIV-hepatitis integration, task shiftingNorth AmericaUSPhiladelphia Department of Public Health (Government)HCVPWID, including homeless and sex workersSyringe exchange programmesAddiction service integrationTask shifting, peer-basedNorth AmericaUSProject IMPACT (NGO)HCVGeneral populationCourthouse lobby and other sitesCourthouse integrationHIV-hepatitis integration, harm reduction.addiction service integrationNorth AmericaUSSt Joseph's Medical Center (Hospital)HBV/HCVGeneral population and those with risk factorsHealth facility clinicsEMRNANorth AmericaUSSt. Lukes-CHI/Project ECHO (Hospital)HCVBirth cohort and among those receiving STD testsPrimary care clinicsTelemedicineDecentralizationNorth AmericaUSC a Difference, Drexel University (Research)HCVOutpatientsPrimary care clinicsSocial mediaHIV-hepatitis integration, decentralizationNorth AmericaUSVirginia Department of Health, Division of Disease Prevention (Government)HCVPWIDMethadone clinics, substance abuse programmesAddiction service integrationDecentralization, task shiftingNorth AmericaUSAsian Liver Center at Stanford University (Research)HBVEmployeesWorkplaceWorkplacePublic-private partnership*SMS* short message system, *HBV* hepatitis B virus, *HCV* hepatitis C virus, *PWID* people who inject drugs, *PLHIV* people living with HIV, *STD* sexually transmitted disease, *EMR* electronic medical records (for risk stratification and clinician reminders)

Survey responses about organizations {#Sec10}
------------------------------------

Respondents to an additional survey showed that the majority (42/64, 66%) of entries were from testing programmes initiated in the past 3 years. Many of these (45/64, 71%) also provided HIV testing. The programmes highlighted a number of barriers to effective testing and treatment in the brief survey, which were common across countries, testing models, and types of organization. The most frequent barriers were lack of hepatitis awareness among the public and subpopulations (25/64, 39%), lack of testing supplies (25/64, 39%), insufficient funding (10/64, 16%), lack of knowledge among healthcare providers and community outreach workers (10/64, 16%), insufficient linkage (9/64, 14%), lack of drug access (8/64, 13%), stigma (4/64, 6%), and local or national laws on illicit drugs (3/64, 5%). A high proportion of organizations highlighted the need for additional support in terms of resources (50/64, 78%), communications (48/64, 75%), and technical expertise (35/64, 55%).

Quality of entries {#Sec11}
------------------

In general, the quality of entries was high (Fig. [2](#Fig2){ref-type="fig"}), with an overall mean score across all judges and based on the four different component scores of 5.65. 31 (46%) of entries received an overall mean of greater than 6.0, and received a commendation certificate from EASL (Table [1](#Tab1){ref-type="table"}). Sixteen submissions were included as short case studies in the chapter on service delivery model in the 2017 WHO hepatitis testing guidelines.Fig. 2Histogram showing range of scores submitted to the global hepatitis innovation contest (*n* = 64)

Social media metrics {#Sec12}
--------------------

Video and website analytics suggested moderate engagement over the 6 weeks of the call for entries. By the end of the call for entries on March 1st, the video announcement had been viewed 453 times in 87 countries (this was 116 times in 37 countries within 2 weeks of the announcement). Website metrics showed that fewer individuals had accessed the announcements in Sub-Saharan African countries and in Latin America. For example, the respective number of website views early in the contest over 5 days (27-31 January) were: Africa (6), Americas (58), Eastern Mediterranean (2), Europe (114), South-East Asia (4), and Western Pacific (24). Access to both video and website analytics helped us to subsequently target further announcements through regional networks that reached those under-represented regions leading to modest increases in views from those regions. Targeting was achieved by the Steering Committee contacting regional networks to promote the contest within their specific region.

Costs {#Sec13}
-----

We examined the costs of the contest solely from the perspective of the contest organisation, and not the costs associated with implementation of the testing approaches. There was no specific funding to support the conduct of the contest. All steering committee members and organizers of the contest volunteered their time, while ILC-EASL supported the cost of having finalists travel to and attend the EASL conference. The Office of the WHO in the Southeast Region supported the cost of travel and registration at the World Hepatitis Day event in India.

Discussion {#Sec14}
==========

This global innovation contest led by a multi-sectoral steering committee attracted 64 entries describing different approaches to hepatitis B and C testing in 27 countries. Overall, the contest was straightforward to organize and implement over a four-month period. The contest elicited high-quality submissions from multiple institutions and community organizations across all geographic regions. There were several distinct positive outcomes from this initiative. First, the inclusion of a range of examples of different service delivery models for testing in different populations and settings as case studies in the 2017 WHO hepatitis testing guidelines will be of practical value to countries and programmes as they start hepatitis testing activities. Second, the contest succeeded in engaging multiple organisations who may be in a position to undertake more formal evaluation of their testing models, as well as provide input on future hepatitis testing and treatment policy. Third, the contest also served as an opportunity for non-governmental organizations to raise their profile and obtain recognition for their work.

The contest identified a range of hepatitis B and C testing approaches that can be used in both community settings and health facilities such as integrated HIV-hepatitis testing; use of social media to promote uptake of testing; workplace testing; testing camps; using emergency departments to promote testing; use of electronic medical record prompts to flag higher risk patients for targeted testing. In addition, the contest identified innovative testing approaches to reach different populations, such as PWID, prisoners and other high-risk groups, migrants and relatives of people living with hepatitis B or C.

The highlighting of the effectiveness of integration of hepatitis testing within other programmes (eg. HIV, mental health services), use of electronic and other reminders to prompt testing, and use of community-based lay providers to deliver testing is consistent with studies showing their effectiveness from both HIV \[[@CR31]\] and hepatitis care \[[@CR11]\]. In particular, the availability of an existing laboratory and clinical infrastructure, trained personnel and funding streams presents a key opportunity to build hepatitis testing into existing HIV testing programmes \[[@CR32]--[@CR35]\]. However, the development of integrated HIV and hepatitis testing will require additional training and resources \[[@CR36]\].

The contest also identified a number of well recognized barriers to hepatitis testing, in particular poor awareness among the general public and limited access to test kits \[[@CR37]--[@CR39]\]. This finding is consistent with other reports from LMICs \[[@CR37], [@CR38]\]. Poor awareness of hepatitis B and C is likely related to many factors, including limited resources for campaigns \[[@CR40]\], a relative lack of celebrity ambassadors for hepatitis \[[@CR41], [@CR42]\], and the asymptomatic nature of chronic viral hepatitis in many cases \[[@CR43]\]. These challenges are consistent with experience reported from other innovation contests focused on promoting HIV testing \[[@CR16], [@CR19]\].

We identified several key features that may have contributed to success of this contest. First, the establishment of a diverse steering committee (including individuals in academia, civil society, government, WHO, medicine, and public health) helped disseminate the call for entries and evaluate entries. Second, we offered incentives to participate that included presentation at international conferences and potential inclusion within the WHO guidelines which may have been important in motivating participation. Although the profiles provided were brief, several contest submissions have since published more detailed descriptions of their programmes and evidence of impact \[[@CR44]--[@CR49]\]. Third, real-time tracking of social media analytics during the contest enhanced subsequent contest promotion towards under-represented regions.

However, there were several limitations to the use of a contest approach to identify innovative models. First, this contest relied on the internet, especially social media, to distribute the call for entries and submit an entry. As a result, contest entries were not representative of all regions, settings, testing models, and populations. We received fewer submissions from Latin America and Africa, and only three entries in non-English languages despite announcing the call for submissions in six languages. This may be related to insufficient dissemination through those regional networks, less internet access, and fewer ongoing hepatitis testing programmes in those settings. Other crowdsourcing contests have demonstrated the additional value of in-person promotion \[[@CR16]\]. Second, the evaluation of quality of submissions was only based on a 300 word description, without further opportunity to clarify or extend. Importantly, only just over half of entries formally evaluated the impact of their programme, and we further noted that several programmes expressed challenges in funding, indicating uncertainty about the financial viability and sustainability of some of these approaches.

Conclusions {#Sec15}
===========

In conclusion, our experience suggests that this contest was a useful way of eliciting a wide range of programmatic experience that can supplement and enrich formal evidence reviews to inform guidelines and policy, and maybe applicable to other areas. Case studies were included in the 2017 WHO viral hepatitis testing guidelines, as they were in the 2015 WHO consolidated guidelines on HIV testing \[[@CR31]\]. The inclusion of good practice examples may serve as a useful model for future international guidelines. However, there remains a need for more systematic evaluation of these different service delivery approaches in different populations. Ultimately, countries will need to identify the most appropriate mix of facility and community based testing opportunities according to local epidemiology, current testing coverage, existing health-care and testing infrastructure and services, and available financial and human resources.

Additional file {#Sec16}
===============

Additional file 1:HepTestContest Call for Entries. This provides the logo, call for entries, and related information released to solicit entries. (DOCX 38 kb)
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